Search





Search





News

All

Editors' Picks

Stocks

Indices

Market Movers

Commodities

Cryptocurrencies

Forex

Earnings

Transcripts

Technical Analysis

Economic Indicator

Other

Allogene Therapeutics (ALLO) Q2 2026 Earnings Call: ALPHA3 Site Expansion and Pipeline Updates

Allogene Therapeutics’ Q2 2026 earnings call covers ALPHA3’s 100-site target, FDA designations, ALLO-316 results and ALLO-329’s Q4 update.

Allogene Therapeutics Inc

TradingKey

Fri, Aug 14

Applied Materials (AMAT) Fiscal Q3 2026 Earnings Call: Revenue Hits $9.1 Billion

Applied Materials fiscal Q3 2026 revenue rose 25% to $9.1 billion. AMAT guided Q4 revenue to $10.25 billion as AI, DRAM and packaging demand strengthened.

Applied Materials Inc

TradingKey

Fri, Aug 14

Altimmune (ALT) Q2 2026 Earnings Call: PERFORMA Starts, Cash Reaches $519M

Altimmune Q2 2026 earnings call: PERFORMA Phase III enrollment begins, RECLAIM AUD data support pivotal planning, and cash reaches $519 million.

TradingKey

Fri, Aug 14

AIRO Q2 2026 Earnings Call: Revenue Jumps 76%, Drone Backlog Reaches $163M

AIRO Q2 2026 earnings call: revenue rose 76% to $43.2 million, gross margin reached 64%, drone backlog hit $163 million, and guidance was reiterated.

AIRO Group Holdings Inc

TradingKey

Fri, Aug 14

AIxCrypto Holdings (AIXC) Q2 2026 Earnings Call: RoboShare Push Amid Tight Liquidity

AIxCrypto Holdings (AIXC) Q2 2026 earnings call: net loss narrowed sequentially to $4.19 million as RoboShare became the priority amid tight liquidity.

AIxCrypto Holdings Ord Shs

TradingKey

Fri, Aug 14

AFCG Q2 2026 Earnings Call: NAV Rises, Pipeline Reaches $1.3 Billion

AFCG’s Q2 2026 earnings call covered $3.5 million in net investment income, $8.25 NAV per share, a 13.2% portfolio yield and a $1.3 billion pipeline.

Advanced Flower Capital Inc

TradingKey

Fri, Aug 14

Applied Industrial Technologies (AIT) Fiscal Q4 2026 Earnings Call: Organic Sales Rise 9.7%

Applied Industrial Technologies’ fiscal Q4 2026 sales rose 10.4% as margins expanded. Review AIT’s segment results and fiscal 2027 guidance.

Applied Industrial Technologies Inc

TradingKey

Fri, Aug 14

AudioEye (AEYE) Q2 2026 Earnings Call: EBITDA Guidance Raised

AudioEye Q2 2026 revenue rose 9% to $10.7 million, ARR reached $42.3 million, and management raised full-year adjusted EBITDA guidance.

TradingKey

Fri, Aug 14

Aebi Schmidt (AEBI) Q2 2026 Earnings Call: EBITDA Up 22%, Backlog Near $1.3B

Aebi Schmidt Q2 2026 earnings call: sales rose 9.4% to $496 million, adjusted EBITDA gained 22%, backlog reached $1.3 billion, and guidance was confirmed.

Aebi Schmidt Holding AG

TradingKey

Fri, Aug 14

ADC Therapeutics (ADCT) Q2 2026 Earnings Call: LOTIS-5 FDA Concerns, $219.1M Cash

ADC Therapeutics Q2 2026 earnings call: ZYNLONTA revenue reached $18.6 million, while FDA concerns clouded the LOTIS-5 regulatory path.

ADC Therapeutics SA

TradingKey

Fri, Aug 14

Aethlon Medical (AEMD) Fiscal Q1 2027 Earnings Call: Oncology Trial Enters Final Cohort

Aethlon Medical’s fiscal Q1 2027 call covered $1.6M in operating expenses, $4.9M in cash and progress in the final oncology trial cohort.

Aethlon Medical Inc

TradingKey

Fri, Aug 14

Alpha Cognition (ACOG) Q2 2026 Earnings Call: ZUNVEYL Sales Rise 71%

Alpha Cognition’s Q2 2026 earnings call covered $6.0M in ZUNVEYL sales, 71% sequential growth, stronger adoption and lower expense guidance.

Alpha Cognition Inc

TradingKey

Fri, Aug 14

Abeona Therapeutics (ABEO) Q2 2026 Earnings Call: ZEVASKYN Revenue Rises 31%

Abeona Therapeutics (ABEO) Q2 2026 earnings call: ZEVASKYN revenue rose 31% QoQ to $11.4M, seven QTCs were active, and cash totaled $146.8M.

Abeona Therapeutics Inc

TradingKey

Fri, Aug 14

AADX Q2 2026 Earnings Call: Revenue Rises 47.4%, Backlog Tops $1.1 Billion

Applied Aerospace & Defense's Q2 2026 earnings call covered 47.4% revenue growth, backlog above $1.1 billion and maintained full-year guidance.

Applied Aerospace and Defense Ord Shs

TradingKey

Fri, Aug 14

Acumen Pharmaceuticals (ABOS) Q2 2026 Earnings Call: ALTITUDE-AD Readout Due Late 2026

Acumen Pharmaceuticals’ Q2 2026 earnings call covered $110.2 million in cash, the late-2026 ALTITUDE-AD readout and its mid-2027 EBD IND target.

Acumen Pharmaceuticals Inc

TradingKey

Fri, Aug 14

1...19 20 21 22 23

23/23

Featured Tools

marketing_marketsTitle

calendar_economicCalendar

Economic Calendar

search.intelligent.strategy

article_asider_weekly_report

Popular Instruments

link

Name

Price

Chg%

link

Semiconductor Stocks Buck Trend as Micron Rises Over 4%; Trump Demands Big Fed Rate Cut

Three Major Index Futures Mixed Pre-Market Ahead of Non-Farm Payrolls; Nvidia, Tesla, Oracle, Lululemon in Focus

【US Pre-Market】Nonfarm Payrolls Due Tonight as Gold Nears $4,500, Bitcoin Tops $81,000, Lululemon Plunges 19%

US Stocks Fall, Dow Drops 270 Points; SOX Bucks Trend to Gain Over 3% Led by Memory, Optical Communication Stocks; SanDisk Rises Nearly 12%, Tesla Drops Almost 6%

Micron Plans to Double Monthly HBM Capacity to 100,000 Wafers to Catch Up With Samsung and SK Hynix

link

XRP (XRPUSD) Fluctuated Significantly on Sep 5: Key Variables Behind the Move

2 hours ago

Solana (SOLUSD) Is up 1.00% on Sep 5: What Are the Risk Factors?

6 hours ago

BNB (BNBUSD) Suddenly Goes up 1.27% on Sep 5: What's Driving This

8 hours ago

Fair Isaac Corp Stock (FICO) Closed Down by 16.68% on Sep 4: What Investors Need To Know

18 hours ago

Eaton Corporation PLC Stock (ETN) Closed Up by 3.46% on Sep 4: A Full Analysis

18 hours ago